Why the study?
Does phospholamban (PLN) ablation improve in vivo cardiac function and hypertrophy in genetic mouse models of hypertrophy and cardiac failure?
Does phospholamban (PLN) ablation improve in vivo cardiac function and hypertrophy in genetic mouse models of hypertrophy and cardiac failure?
While phospholamban ablation normalizes contractility in isolated cardiomyocytes, it fails to rescue the cardiomyopathic phenotype in genetic mouse models of hypertrophy.
No takes yet. Share an insight, caveat, or question.
PLN ablation fails to rescue in vivo phenotypes despite myocyte benefits; leaves open its therapeutic potential in genetic cardiomyopathies.
Song et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: